https://www.selleckchem.com/peptide/dulaglutide.html ng and Outcomes [PROVE-HF]; NCT02887183). Sacubitril/valsartan favorably affects natriuretic peptide levels, reverse cardiac remodeling, and health status in patients with HFrEF with and without T2DM. (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183). The authors sought to evaluate the association of heart failure hospitalization (HFH) with guideline-directed medical therapy (GDMT) prescribing patterns among patients with heart failure with reduced ejection fraction (HFrEF). HFH represents an important opportunity to titrate GDMT among patients with HFrEF. The CHAMP-HF (Change the Management of Patients With HeartFailure) registry is a prospective registry of adults with HFrEF (ejection fraction≤40%). Using data from the CHAMP-HF registry (N=4,365), adjusted time-to-event models were created to study the association of HFH with GDMT prescribing patterns. HFH (compared with no HFH) was positively associated with initiation of angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB), angiotensin receptor-neprilysin inhibitor, beta-blocker, and mineralocorticoid receptor antagonist (MRA). HFH positively associated with dose escalation of ACE inhibitor/ARB (probability ratio 1.71, 95% confidence interval [CI] 1.36 to 2.16) and Mth changes in GDMT, including initiation, dose escalation, discontinuation, and dose de-escalation. De-escalation/discontinuation of GDMT after HFH associated with increased risk of all-cause mortality. Educational endeavors are needed to ensure GDMT is not inappropriately held in the setting of HFH. For those in whom GDMT must be held/decreased, improvement tools at discharge and post-discharge titration clinics may help ensure lifesaving GDMT regimens remain optimized. The aim of this study was to assess the clinical course and outcomes of all heart transplant recipients affected by coronavirus disease-2